NCT05180097 is a Phase 2 clinical trial of Gemcitabine in Hodgkin Lymphoma, sponsored by Canadian Cancer Trials Group.

Who is sponsoring NCT05180097?

NCT05180097 is sponsored by Canadian Cancer Trials Group.

What drugs are being tested in NCT05180097?

Interventions in NCT05180097: Gemcitabine, Dexamethasone, Cisplatin, Brentuximab vedotin, Pembrolizumab.

What condition does NCT05180097 study?

NCT05180097 studies Hodgkin Lymphoma.

Is NCT05180097 still recruiting?

NCT05180097 is currently recruiting now. Last updated 2 February 2026.

Last reviewed 2026-02-02 · How we verify

NCT05180097

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Recruiting now Phase 2 Last updated 2 February 2026

What this trial tests

Phase 2 trial testing Gemcitabine in Hodgkin Lymphoma in 84 participants. Currently enrolling.

Timeline

1 November 2022

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	Canadian Cancer Trials Group
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	84
Start date	1 November 2022
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	18 locations across Canada, Australia

Drugs / interventions tested

Gemcitabine (gemcitabine) — full drug profile →
Dexamethasone (dexamethasone) — full drug profile →
Cisplatin (cisplatin) — full drug profile →
Brentuximab vedotin — full drug profile →
Pembrolizumab (pembrolizumab) — full drug profile →

Conditions studied

Hodgkin Lymphoma — all drugs for Hodgkin Lymphoma →

Sponsor

Canadian Cancer Trials Group — full company profile →

Who can join

18 and older, any sex, with Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is being done to determine if two new drugs can shrink or eliminate classical Hodgkins lymphoma.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Checkpoint inhibition in hematologic malignancies.
Tsumura A, Levis D, Tuscano JM. · · 2023 · cited 14× · PMID 37920162 · DOI 10.3389/fonc.2023.1288172
Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies.
Shang J, Hu S, Wang X. · · 2024 · cited 13× · PMID 38396050 · DOI 10.1186/s40164-024-00481-y
Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas.
Li Z, Guo W, Bai O. · · 2023 · cited 11× · PMID 38188299 · DOI 10.3389/fonc.2023.1301437
Antibody-drug conjugates combinations in cancer treatment.
Pretelli G, Mati K, Motta L, Stathis A. · · 2024 · cited 5× · PMID 38966169 · DOI 10.37349/etat.2024.00243
Patient-reported outcomes in Hodgkin lymphoma trials: a systematic review.
Oliva EN, Ionova T, Laane E, Csenar M, et al · · 2024 · cited 4× · PMID 38544841 · DOI 10.3389/fonc.2024.1353101
Has PD-1 blockade changed the standard of care for cHL?
Kuczmarski TM, Lynch RC. · · 2024 · cited 1× · PMID 39643988 · DOI 10.1182/hematology.2024000574

Verify or expand the search:

Other trials of Gemcitabine

Trials testing the same drug.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07504588 — Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and · Phase 2 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting
NCT07275216 — Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Stand · Phase 2 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting

Other recruiting trials for Hodgkin Lymphoma

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT06176690 — Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas · Phase 1 · recruiting
NCT07002216 — BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma · Phase 2 · recruiting

Other Canadian Cancer Trials Group trials

Trials by the same sponsor.

NCT07390435 — Feasibility and Acceptability of Collecting Sociodemographic Data in CCTG Trials · not yet recruiting
NCT07297667 — GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours · Phase 1 · not yet recruiting
NCT06630273 — Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes in Patients Treated With Immuno-Oncotherape · not yet recruiting
NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07341191 — Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05180097 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Canadian Cancer Trials Group
Last refreshed: 2 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05180097.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing